4basebio (LON:4BB – Get Free Report) posted its earnings results on Monday. The company reported GBX (0.57) EPS for the quarter, Digital Look Earnings reports.
4basebio Stock Down 0.5%
LON 4BB traded down GBX 2.70 on Tuesday, hitting GBX 559.80. 261 shares of the stock were exchanged, compared to its average volume of 1,353. The company has a 50-day moving average price of GBX 511.05 and a 200-day moving average price of GBX 510.01. 4basebio has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 820. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market cap of £86.69 million, a PE ratio of -5.14 and a beta of 1.09.
Analyst Ratings Changes
Separately, Royal Bank Of Canada lowered their price objective on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of GBX 1,400.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Recommended Stories
- Five stocks we like better than 4basebio
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
